MarketResearchNest.com adds “C-C Chemokine Receptor Type 5 (CHEMR13 Or HIV 1 Fusion Coreceptor Or CD195 Or CCR5) - Pipeline Review, H2 2017” new report to its research database. The report spread across in 72 pages with table and figures in it.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Browse full table of contents and data tables at
Featured News & Press Releases 63
Jun 01, 2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 63
May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 63
May 01, 2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 64
Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 64
Apr 11, 2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 64
Feb 15, 2017: CMC Biologics Enters into Manufacturing Agreement with CytoDyn 65
Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 65
Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 66
Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 66
Dec 12, 2016: CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV 67
Nov 16, 2016: CytoDyn Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 67
Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 68
Oct 24, 2016: CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial 68
Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69
Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70
Companies mentioned in this report includes:
Allergan Plc ,American Gene Technologies International Inc,Bristol-Myers Squibb Company,ChemoCentryx Inc ,Cytodyn Inc ,GlaxoSmithKline Plc ,Pharis Biotec GmbH ,TaiwanJ Pharmaceuticals Co Ltd
Order a Premium Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=253135
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Enquiry before buying at https://www.marketresearchnest.com/enquirybuy.php?reportid=253135
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain
Connect with us: Google+ | LinkedIn | Twitter | Facebook